{"id":"https://openalex.org/W3216856426","doi":"https://doi.org/10.1212/wnl.94.15_supplement.4492","title":"Initial Data From the Ongoing ENDYMION Open-label Extension Trial of Soticlestat (TAK-935/OV935) in Participants With Developmental and/or Epileptic Encephalopathies (DEE) (4492)","display_name":"Initial Data From the Ongoing ENDYMION Open-label Extension Trial of Soticlestat (TAK-935/OV935) in Participants With Developmental and/or Epileptic Encephalopathies (DEE) (4492)","publication_year":2020,"publication_date":"2020-04-14","ids":{"openalex":"https://openalex.org/W3216856426","doi":"https://doi.org/10.1212/wnl.94.15_supplement.4492","mag":"3216856426"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.94.15_supplement.4492","doi":"https://doi.org/10.1212/wnl.94.15_supplement.4492","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.94.15_supplement.4492","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021099852","display_name":"Jonathan J. Halford","orcid":"https://orcid.org/0000-0003-1681-6744","observed_orcids":["https://orcid.org/0000-0003-1681-6744"]},"institutions":[{"id":"https://openalex.org/I153297377","display_name":"Medical University of South Carolina","ror":"https://ror.org/012jban78","country_code":"US","type":"education","lineage":["https://openalex.org/I153297377"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Halford","raw_affiliation_strings":["Medical University of South Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical University of South Carolina","institution_ids":["https://openalex.org/I153297377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079209617","display_name":"Dimitrios Arkilo","orcid":"https://orcid.org/0000-0002-7487-2747","observed_orcids":["https://orcid.org/0000-0002-7487-2747"]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Dimitrios Arkilo","raw_affiliation_strings":["Takeda Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004004308","display_name":"Mahnaz Asgharnejad","orcid":"https://orcid.org/0000-0001-8060-2148","observed_orcids":["https://orcid.org/0000-0001-8060-2148"]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Mahnaz Asgharnejad","raw_affiliation_strings":["Takeda Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068296661","display_name":"Celia Zinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166081","display_name":"Ovid Therapeutics (United States)","ror":"https://ror.org/05wmdnq05","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Celia Zinger","raw_affiliation_strings":["Ovid Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ovid Therapeutics","institution_ids":["https://openalex.org/I4210166081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100706861","display_name":"Shijie Chen","orcid":"https://orcid.org/0000-0001-7398-6008","observed_orcids":["https://orcid.org/0000-0001-7398-6008"]},"institutions":[{"id":"https://openalex.org/I4210166081","display_name":"Ovid Therapeutics (United States)","ror":"https://ror.org/05wmdnq05","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shijie Chen","raw_affiliation_strings":["Ovid Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ovid Therapeutics","institution_ids":["https://openalex.org/I4210166081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109218920","display_name":"Matthew J. During","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166081","display_name":"Ovid Therapeutics (United States)","ror":"https://ror.org/05wmdnq05","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew During","raw_affiliation_strings":["Consultant, Ovid Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Consultant, Ovid Therapeutics","institution_ids":["https://openalex.org/I4210166081"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038885649","display_name":"Jacqueline A. French","orcid":"https://orcid.org/0000-0003-2242-8027","observed_orcids":["https://orcid.org/0000-0003-2242-8027"]},"institutions":[{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline French","raw_affiliation_strings":["New York University Langone"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York University Langone","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5081,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.66122332,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"94","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12267","display_name":"Diet and metabolism studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/developmental-and-epileptic-encephalopathy","display_name":"developmental and epileptic encephalopathy","score":0.9049999713897705},{"id":"https://openalex.org/keywords/24s-hydroxycholesterol","display_name":"24S-hydroxycholesterol","score":0.9049999713897705},{"id":"https://openalex.org/keywords/seizure-frequency-reduction","display_name":"seizure frequency reduction","score":0.8220000267028809},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8989999890327454},{"id":"https://openalex.org/keywords/drug-resistant-epilepsy","display_name":"drug-resistant epilepsy","score":0.7250000238418579},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.8669999837875366}],"concepts":[{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.44532835483551025},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.4359200596809387},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4020766019821167},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3692004680633545},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.33489930629730225}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.94.15_supplement.4492","doi":"https://doi.org/10.1212/wnl.94.15_supplement.4492","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.94.15_supplement.4492","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389446405","https://openalex.org/W4389460487","https://openalex.org/W3159699587","https://openalex.org/W4367303714","https://openalex.org/W4407709609","https://openalex.org/W4389460507","https://openalex.org/W2805277741","https://openalex.org/W4399732669","https://openalex.org/W3198538026","https://openalex.org/W4362520887"],"abstract_inverted_index":{"Objective:":[0],"The":[1,105,153],"primary":[2],"objective":[3],"of":[4,14,36,44,62,84,107,151,166,174,184,217,223,246,255,260],"ENDYMION":[5,76,190],"is":[6,32,41,57,77,225],"to":[7,26,51,87,194,242],"assess":[8],"the":[9,187,204,228,243,252,258],"long-term":[10],"safety":[11,198],"and":[12,21,73,123,145,170,199,466],"tolerability":[13,200],"soticlestat":[15,85,102,192,256],"(TAK-935/OV935)":[16],"in":[17,92,99,121,186,211,387,419,425],"participants":[18,93,161],"with":[19,94,203,220,282,311,332,354,376,408],"developmental":[20],"epileptic":[22,261],"encephalopathies":[23],"(DEE);":[24],"secondarily,":[25],"evaluate":[27],"seizure":[28,131,218],"frequency.":[29],"Background:":[30],"DEE":[31,95],"a":[33,58,78,100,196,274,303,324,346,368,400],"heterogeneous":[34],"group":[35],"rare":[37],"highly-refractory":[38],"epilepsies.":[39],"Soticlestat":[40,65],"an":[42,432],"inhibitor":[43],"cholesterol":[45,50],"24-hydroxylase":[46],"that":[47],"converts":[48],"neuronal":[49],"24":[52],"S":[53],"-hydroxycholesterol":[54],"(24HC),":[55],"which":[56,422,426],"positive":[59],"allosteric":[60],"modulator":[61],"NMDA":[63],"receptors.":[64],"may":[66],"also":[67],"reduce":[68],"inflammation":[69],"through":[70],"glial":[71],"modulation":[72],"neuroprotection.":[74],"Design/Methods:":[75],"prospective,":[79],"multi-center,":[80],"open-label":[81,238],"extension":[82],"study":[83],"(up":[86],"300":[88],"mg":[89],"BID,":[90],"oral)":[91],"who":[96],"have":[97],"participated":[98],"previous":[101,205],"trial.":[103],"Results:":[104],"majority":[106],"reported":[108],"adverse":[109,126],"events":[110,127],"(abdominal":[111],"pain,":[112],"nausea,":[113],"pyrexia,":[114],"bronchial":[115],"wall":[116],"thickening,":[117],"rales)":[118],"were":[119,128],"mild":[120],"severity,":[122],"no":[124,231],"serious":[125],"observed.":[129],"Median":[130],"frequency":[132],"reduction":[133,216],"was":[134,162,429],"46.4%":[135],"following":[136,141,147],"13\u201324":[137],"weeks":[138,143,149],"(n=7),":[139,144],"82%":[140],"25\u201336":[142],"90%":[146],"37\u201348":[148],"(n=4)":[150],"treatment.":[152],"longest":[154],"seizure-free":[155],"consecutive":[156],"duration":[157,222],"by":[158,227],"two":[159],"different":[160],"264":[163],"days":[164,172],"(out":[165,173],"350":[167],"treatment":[168,176,224,259],"days)":[169],"150":[171],"336":[175],"days),":[177],"respectively.":[178],"Conclusions:":[179],"In":[180],"this":[181],"small":[182],"number":[183,245],"subjects":[185],"open":[188],"label":[189],"study,":[191],"continues":[193],"show":[195],"favorable":[197],"profile,":[201],"consistent":[202],"Phase":[206],"2":[207],"TAK-935-2001":[208],"trial":[209],"results":[210],"adult":[212],"DEE.":[213],"A":[214],"progressive":[215],"activity":[219],"longer":[221],"suggested":[226],"data,":[229],"although":[230],"definite":[232],"conclusion":[233],"can":[234],"be":[235],"drawn":[236],"about":[237],"sustained":[239],"efficacy":[240],"due":[241],"low":[244],"subjects.":[247],"But":[248],"these":[249],"data":[250],"support":[251,290,439],"continued":[253],"development":[254],"for":[257,270,299,320,342,364,396],"encephalopathies.":[262],"Disclosure:":[263],"Dr.":[264,285,314,358,380,390,412,427,434],"Halford":[265,286],"has":[266,287,295,316,338,360,392,436],"received":[267,288,296,317,339,361,393,437],"personal":[268,297,318,340,362,394],"compensation":[269,298,319,341,363,395],"consulting,":[271,300,321,343,365,397],"serving":[272,301,322,344,366,398],"on":[273,302,323,345,367,399],"scientific":[275,304,325,347,369,401],"advisory":[276,305,326,348,370,402],"board,":[277,306,327,349,371,403],"speaking,":[278,307,328,350,372,404],"or":[279,308,329,351,373,405],"other":[280,309,330,352,374,406],"activities":[281,310,331,353,375,407],"Brain":[283,292],"Sentinel.":[284],"research":[289,424,438],"from":[291,440],"Sentinel.Dr.":[293],"Arkilo":[294],"Takeda":[312,333],"Pharmaceuticals.":[313],"Asgharnejad":[315],"Pharmaceuticals":[334],"International,":[335],"Inc.Dr.":[336],"Zinger":[337],"Ovid":[355,377,388,409,420],"Therapeutics":[356,378,410,421],"(employer).":[357],"Chen":[359,381],"Inc.":[379],"holds":[382,414],"stock":[383,385,415,417],"and/or":[384,416],"options":[386,418],"Therapeutics.":[389],"During":[391,413,428],"(consultant).":[411],"sponsored":[423],"involved":[430],"as":[431],"investigator.":[433],"French":[435],"Adamas,":[441],"Addex,":[442],"Anavex,":[443],"Arvelle":[444],"Therapeutics,":[445,455,462],"Axovant,":[446],"Biogen,":[447],"BioMotiv/Koutif,":[448],"Blackfynn,":[449],"Bloom":[450],"Science,":[451],"BridgeValley,":[452],"Cavion,":[453],"Cerebral":[454],"Cerevel,":[456],"Clinilabs,":[457],"Crossject,":[458],"Eisai,":[459],"Encoded,":[460],"Engage":[461],"Epitel,":[463],"Fortress":[464],"Biotech,":[465],"GW":[467],"Pharma.":[468]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":3}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2021-12-06T00:00:00"}